凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
莱茵生物(002166)公告正文

莱茵生物:2013年第一季度报告全文

公告日期 2013-04-24
股票简称:莱茵生物 股票代码:002166
桂林莱茵生物科技股份有限公司
    2013 年第一季度报告
         2013 年 04 月
                                            桂林莱茵生物科技股份有限公司 2013 年第一季度报告全文
                              第一节 重要提示
    公司董事会、监事会及董事、监事、高级管理人员应当保证季度报告内容的真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。
    公司负责人姚新德、主管会计工作负责人周庆伟及会计机构负责人(会计主管人员)张为鹏声明:保证季度报告中财务报表的真实、准确、完整。
    所有董事均已出席了审议本次季报的董事会会议。
                                                            桂林莱茵生物科技股份有限公司 2013 年第一季度报告全文
                            第二节 主要财务数据及股东变化一、主要财务数据本报告期对以前期间财务数据是否进行了追溯调整或重述□ 是 √ 否
                                                                                                本报告期比上年同期增减
                                         2013 年 1-3 月              2012 年 1-3 月
                                                                                                        (%)
    营业收入(元)                                 95,142,400.97                35,648,461.76                        166.89%
    归属于上市公司股东的净利润(元)                 1,805,506.51              -12,527,545.75                        114.41%归属于上市公司股东的扣除非经常性损
                                                 1,334,999.12              -13,278,479.08                        110.05%益的净利润(元)
    经营活动产生的现金流量净额(元)               -89,476,868.08               42,689,157.10                        -309.6%
    基本每股收益(元/股)                                       0.01                        -0.10                      110%
    稀释每股收益(元/股)                                       0.01                        -0.10                      110%
    加权平均净资产收益率(%)                                 1.1%                     -5.62%                         6.72%
                                                                                                本报告期末比上年度期末
                                       2013 年 3 月 31 日          2012 年 12 月 31 日
                                                                                                       增减(%)
    总资产(元)                                 1,189,605,623.16              908,157,355.03                        30.99%
    归属于上市公司股东的净资产(元)              164,920,650.90               163,169,199.52                         1.07%非经常性损益项目和金额√ 适用 □ 不适用
                                                                                                                 单位:元
                         项目                               年初至报告期期末金额                      说明
    非流动资产处置损益(包括已计提资产减值准备的冲销部分)                      -1,119.00计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                          533,000.00一标准定额或定量享受的政府补助除外)
    计入当期损益的对非金融企业收取的资金占用费                                184,000.00
    除上述各项之外的其他营业外收入和支出                                     -199,373.61
    所得税影响额                                                               46,000.00
    合计                                                                      470,507.39                    --
                                                             桂林莱茵生物科技股份有限公司 2013 年第一季度报告全文二、报告期末股东总数及前十名股东持股情况表
                                                                                                             单位:股
    报告期末股东总数                                                                                                40,246
                                                前 10 名股东持股情况
                                                                       持有有限售条件         质押或冻结情况
       股东名称          股东性质   持股比例(%)     持股数量
                                                                         的股份数量       股份状态          数量
    秦本军             境内自然人               29.81%       38,613,504         24,230,000 质押                 24,230,000
    姚新德             境内自然人                10.5%       13,601,609         10,201,207 冻结                 10,201,207
    蒋安明             境内自然人                2.39%        3,101,576                   0
    刘蕊               境内自然人                0.34%           440,000                  0
    陈巧云             境内自然人                 0.3%           394,379                  0
    干岳斌             境内自然人                0.26%           340,499                  0辽宁东亚种业有限
                   境内非国有法人            0.24%           309,650                  0公司
    黎科弟             境内自然人                0.23%           302,500                  0
    王龙花             境内自然人                0.19%           250,000                  0国信证券股份有限
    公司客户信用交易 境内非国有法人              0.13%           174,451                  0担保证券账户
                                           前 10 名无限售条件股东持股情况
                                                                                                 股份种类
              股东名称                         持有无限售条件股份数量
                                                                                          股份种类          数量
    秦本军                                                                      38,613,504 人民币普通股         38,613,504
    姚新德                                                                       3,400,402 人民币普通股          3,400,402
    蒋安明                                                                       3,101,576 人民币普通股          3,101,576
    刘蕊                                                                          440,000 人民币普通股             440,000
    陈巧云                                                                        394,379 人民币普通股             394,379
    干岳斌                                                                        340,499 人民币普通股             340,499
    辽宁东亚种业有限公司                                                          309,650 人民币普通股             309,650
    黎科弟                                                                        302,500 人民币普通股             302,500
    王龙花                                                                        250,000 人民币普通股             250,000国信证券股份有限公司客户信用交
                                                                              174,451 人民币普通股             174,451易担保证券账户
    上述股东关联关系或一致行动的说      公司股东秦本军先生与蒋安明先生为兄弟关系,属于一致行动人,除上述关联关系以外,
    明                                  公司前 3 大股东之间不存在关联关系或一致行动,其他股东之间关系不详。
                                                        桂林莱茵生物科技股份有限公司 2013 年第一季度报告全文
                                     第三节 重要事项一、报告期主要会计报表项目、财务指标发生重大变动的情况及原因(一)报告期内资产负债表项目重大变动及原因
                                                                                                     单位:元
            项目                期末余额                     年初余额                     增减比例
    应收账款                            78,523,457.45                   64,119,838.63                      22.46%
    存货                               794,507,152.25                  512,047,927.13                      55.16%
    无形资产                              820,148.35                    24,562,591.57                      -96.66%
    预收款项                             1,274,645.22                        392,671.33                   224.61%
    应付职工薪酬                          162,928.38                        1,915,131.47                   -91.49%
    应交税费                              -200,277.70                       2,083,680.49                  -109.61%
    应付利息                              663,228.54                        1,718,782.95                   -61.41%
    一年内到期的非流动负债               7,835,950.00                   13,269,120.00                      -40.95%
    长期借款                           420,000,000.00                  320,000,000.00                      31.25%
       1、报告期应收账款较期初增加22.46%,主要系营业收入增加未到收款期所致;
       2、报告期存货较期初增加55.16%,主要系工业用地变更为商住用地而增加土地存货所致;
       3、报告期无形资产较期初减少96.66%,系工业用地变更为商住用地而减少土地使用权所致;
       4、报告期预收款项较期初增加224.61%,系预收客户货款增加所致;
       5、报告期应付职工薪酬较期初减少91.49%,主要系报告期发放上年绩效工资所致;
       6、报告期应交税费较期初减少109.61%,主要系报告期取得增值税留底进项增加所致;
       7、报告期应付利息较期初减少61.41%,主要系报告期已支付贷款利息所致;
       8、报告期一年内到期的非流动负债较期初减少40.95%,系报告期偿还部分一年内到期的银行贷款、及按月支付融资租赁款所致;
       9、报告期长期借款较期初增加31.25%,系银行长期借款增加所致;(二)报告期内利润表项目重大变动及原因:
                                                                                                     单位:元
           项目               本期发生额                     上年同期                     增减比例
    营业收入                            95,142,400.97                   35,648,461.76                     166.89%
                                                     桂林莱茵生物科技股份有限公司 2013 年第一季度报告全文
    营业成本                         75,091,629.37                   31,254,352.17                     140.26%
    营业税金及附加                    1,817,798.35                      422,498.01                     330.25%
    管理费用                          5,629,164.91                    8,049,829.91                      -30.07%
    财务费用(含汇兑损失)            8,686,512.58                    6,679,762.56                      30.04%
    投资收益                           251,335.13                       161,994.00                      55.15%
    营业外支出                         201,119.00                          16,842.88                  1094.09%
    少数股东损益                         -4,738.26                         -10,728.62                   55.84%
    其他综合收益                       -318,530.77                         66,329.55                   -580.22%
    1、报告期营业收入较上年同期增加166.89%,系报告期销售额增加及BT项目营业收入增加所致;
    2、报告期营业成本较上年同期增加140.26%,主要系因营业收入增加营业成本相应增加所致;
    3、报告期营业税金及附加较上年同期增加330.25%,主要系因营业收入增加营业税金及附加相应增加所致;
    4、报告期管理费用较上年同期减少30.07%,主要系报告期支付的工资费用及需要计提的设备折旧较上年同期减少所致;
    5、报告期财务费用较上年同期增加30.04%,主要系金融机构借款增加产生的利息增加所致;
    6、报告期投资收益较上年同期增加55.15%,系报告期收到现金分红增加所致;
    7、报告期营业外支出较上年同期增加1,094.09%,主要系报告期因BT项目施工造成树木损害而产生的赔款所致;
    8、报告期少数股东权益较上年同期增加55.84%,主要系报告期子公司亏损减少所致;
    9、报告期其他综合收益较上年同期减少580.22%,系报告期子公司外币报表折算差额所致;(三)报告期内现金流量表项目大幅度变动及原因:
                                                                                                  单位:元
               项目            本期发生额                   上年同期                   增减比例
    经营活动产生的现金流量净额          -89,476,868.08               42,689,157.10                     -309.60%
    投资活动产生的现金流量净额           -2,889,192.20                -3,534,540.50                     18.26%
    筹资活动产生的现金流量净额           95,458,890.99               -43,639,636.85                    318.74%
    1、报告期内经营活动产生的现金流量净额较上年同期减少309.6%,主要系报告期因工业用地变性商住用地支付土地出让金、BT项目工程支出增加所致;
    2、报告期内投资活动产生的现金流量净额较上年同期增加18.26%,主要系报告期支付设备款减少所
                                                               桂林莱茵生物科技股份有限公司 2013 年第一季度报告全文致。
    3、报告期内筹资活动产生的现金流量净额较上年同期增加318.74%,主要系报告期银行贷款增加所致。二、重要事项进展情况及其影响和解决方案的分析说明
    1、2011年11月4日,公司披露了《关于签订日常经营重大合同的公告》。公司及全资子公司LAYN USA与美国嘉吉股份有限公司营养健康事业部正式签订了一份关于甜菊糖最终产品的长期独家《外包加工及供应协议》。根据协议的相关约定,该协议已经自动续约2年至2015年11月1日止。本报告期,公司已收到嘉吉订单金额573.04万美元,尚有568.41万美元未执行。
    2、随着政府“保护漓江,发展临桂,再造一个新桂林”的桂林市城市建设发展战略举措的进一步实施,临桂新区建设速度明显加快。桂林莱茵生物科技股份有限公司(以下简称“公司”)位于临桂秧塘工业园的新建工厂,已不符合临桂新区的整体发展规划。因此,桂林市县政府要求公司尽快完成整体搬迁。公司于2011年3月17日接到桂林市临桂县人民政府文件《关于桂林莱茵生物科技股份有限公司整体搬迁有关问题的批复》(临政复[2011]44号)。详细情况见公司于2011年3月19日披露的《关于公司整体搬迁的提示性公告》,公告编号[2011-007]。
    2013年2月,经初步协商,临桂县人民政府办公室文件(临政办复[2013]10号文)批复同意将公司秧塘工业区工业用地变更为商住用地,市场评估价26,324.4万元,公司原工业用地、地面构建物及附着物、搬迁补偿市场评估20,346.44万元。2013年3月15日,公司2013年度第1次临时股东大会审议通过了《关于公司整体搬迁补偿方案的议案》。2013年3月18日,公司与临桂县国土局签订了新的《土地出让合同》,目前土地出让金及政府搬迁补偿均已按前述金额结清。2013年4月22日,公司收到临桂县人民政府针对该事项的正式文件(临政复[2013]52号文)。根据审计机构意见,该事项对公司财务状况及经营成果的影响需在公司整体搬迁完成后才能确定。
           重要事项概述                             披露日期                         临时报告披露网站查询索引
                                                                              巨潮资讯网 www.cninfo.com.cn,公告编
    BT 项目合同实施进展公告              2013 年 04 月 08 日
                                                                              号 2013-015三、公司或持股 5%以上股东在报告期内或持续到报告期内的承诺事项
             承诺事项                    承诺方            承诺内容       承诺时间       承诺期限      履行情况股改承诺收购报告书或权益变动报告书中所作承诺
                                                             桂林莱茵生物科技股份有限公司 2013 年第一季度报告全文资产重组时所作承诺
                                                      本公司上市时,
                                                      当时持有本公
                                                      司 5%以上股份
                                                      的股东秦本军、
                                                      姚新德、杨晓涛
                                                      及蒋安明向本
                                                      公司出具了《避
                                                      免同业竞争承
                                                      诺函》,承诺:"
                                                      本人将不在中
                                                      国境内外直接
                                                      或间接从事或
                                                      参与任何在商
                                                      业上对股份公
                                     秦本军、姚新     司构成竞争的                                    截至本报告披
                                                                        2007 年 09 月 13
    首次公开发行或再融资时所作承诺       德、杨晓涛及蒋 业务或活动,或                         长期履行   露日,该承诺履
                                                                        日
                                     安明             拥有与股份公                                    行情况正常。
                                                      司存在竞争关
                                                      系的任何经济
                                                      实体、机构、经
                                                      济组织的权益,
                                                      或以其他任何
                                                      形式取得该经
                                                      济实体、机构、
                                                      经济组织的控
                                                      制权,或在该经
                                                      济实体、机构、
                                                      经济组织中担
                                                      任高级管理人
                                                      员或核心技术
                                                      人员。"其他对公司中小股东所作承诺
    承诺是否及时履行                     是
    未完成履行的具体原因及下一步计划     承诺正常履行中。是否就导致的同业竞争和关联交易问题
                                     否作出承诺
    承诺的解决期限                       无。
    解决方式                             无。
    承诺的履行情况                       履行情况正常。
                                                              桂林莱茵生物科技股份有限公司 2013 年第一季度报告全文四、对 2013 年 1-6 月经营业绩的预计2013 年 1-6 月预计的经营业绩情况: 与上年同期相比扭亏为盈与上年同期相比扭亏为盈2013 年 1-6 月净利润与上年同期相比扭亏为盈
                                                                         300    至                            600(万元)2012 年 1-6 月归属于上市公司股东的净利润(万
                                                                                                         -1,780.17元)
                                               公司将继续加大国际市场维护和开拓力度,预计主营植物提取业务销售情
                                               况较好,且毛利率较高产品所占比重较大,销售的产品平均毛利率有较大
                                               提高。同时,公司全资子公司莱茵投资承担的 BT 项目部分工程将可以确
    业绩变动的原因说明                             认部分收益。综上所述原因,预计公司 1-6 月份能实现扭亏为盈。上述盈
                                               利预测仅在基于公司目前可预见的经营环境变化及工程项目施工验收进度
                                               的基础上作出,如果外部环境发生一定变化,将会对公司业绩造成较大影
                                               响,上述业绩预测将存在需要进行调整的风险。
                                                        桂林莱茵生物科技股份有限公司 2013 年第一季度报告全文
                                         第四节 财务报表一、财务报表1、合并资产负债表编制单位:桂林莱茵生物科技股份有限公司
                                                                                                     单位:元
                 项目                        期末余额                               期初余额流动资产:
    货币资金                                              43,871,810.30                         41,151,733.01
    结算备付金
    拆出资金
    交易性金融资产
    应收票据
    应收账款                                              78,523,457.45                         64,119,838.63
    预付款项                                               9,520,751.84                         10,829,553.82
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息                                               7,650,584.72                          7,466,584.72
    应收股利
    其他应收款                                            71,009,466.35                         62,972,865.97
    买入返售金融资产
    存货                                                 794,507,152.25                        512,047,927.13
    一年内到期的非流动资产
    其他流动资产                                           4,553,623.88                          4,553,623.88
    流动资产合计                                            1,009,636,846.79                       703,142,127.16非流动资产:
    发放委托贷款及垫款
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                                          26,030,000.00                         26,030,000.00
                              桂林莱茵生物科技股份有限公司 2013 年第一季度报告全文
    投资性房地产
    固定资产                   150,000,249.38                       151,304,257.66
    在建工程                       100,000.00                          100,000.00
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                       820,148.35                        24,562,591.57
    开发支出
    商誉
    长期待摊费用
    递延所得税资产               3,018,378.64                         3,018,378.64
    其他非流动资产
    非流动资产合计                 179,968,776.37                       205,015,227.87
    资产总计                      1,189,605,623.16                      908,157,355.03流动负债:
    短期借款                   365,147,990.35                       348,457,104.68
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    交易性金融负债
    应付票据
    应付账款                    24,344,785.96                        30,432,593.27
    预收款项                     1,274,645.22                          392,671.33
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                   162,928.38                         1,915,131.47
    应交税费                      -200,277.70                         2,083,680.49
    应付利息                       663,228.54                         1,718,782.95
    应付股利
    其他应付款                  14,124,524.32                        15,304,781.48
    应付分保账款
    保险合同准备金
    代理买卖证券款
                                                             桂林莱茵生物科技股份有限公司 2013 年第一季度报告全文
    代理承销证券款
    一年内到期的非流动负债                                     7,835,950.00                         13,269,120.00
    其他流动负债
    流动负债合计                                                  413,353,775.07                        413,573,865.67非流动负债:
    长期借款                                                 420,000,000.00                        320,000,000.00
    应付债券
    长期应付款                                                   485,003.17                           472,784.48
    专项应付款                                               179,909,426.92
    预计负债
    递延所得税负债
    其他非流动负债                                            10,748,265.00                         10,748,265.00
    非流动负债合计                                                611,142,695.09                        331,221,049.48
    负债合计                                                     1,024,496,470.16                       744,794,915.15所有者权益(或股东权益):
    实收资本(或股本)                                       129,533,760.00                        129,533,760.00
    资本公积                                                  83,217,530.86                         83,217,530.86
    减:库存股
    专项储备
    盈余公积                                                   8,834,943.24                          8,834,943.24
    一般风险准备
    未分配利润                                                -56,347,052.43                       -58,152,558.94
    外币报表折算差额                                            -318,530.77                           -264,475.64
    归属于母公司所有者权益合计                                    164,920,650.90                        163,169,199.52
    少数股东权益                                                 188,502.10                           193,240.36
    所有者权益(或股东权益)合计                                  165,109,153.00                        163,362,439.88负债和所有者权益(或股东权益)总
                                                             1,189,605,623.16                       908,157,355.03计
    法定代表人:姚新德                       主管会计工作负责人:周庆伟                      会计机构负责人:张为鹏2、母公司资产负债表编制单位:桂林莱茵生物科技股份有限公司
                                                                                                          单位:元
                  项目                            期末余额                               期初余额
                                  桂林莱茵生物科技股份有限公司 2013 年第一季度报告全文流动资产:
    货币资金                       28,916,858.86                         10,785,342.58
    交易性金融资产
    应收票据
    应收账款                       50,741,198.33                         71,119,490.32
    预付款项                        3,406,866.52                          4,714,809.09
    应收利息
    应收股利
    其他应收款                    131,388,597.01                        198,011,210.59
    存货                          408,583,728.32                        139,231,656.97
    一年内到期的非流动资产
    其他流动资产                    3,780,290.55                          3,780,290.55
    流动资产合计                      626,817,539.59                        427,642,800.10非流动资产:
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                  144,184,924.59                        144,184,924.59
    投资性房地产
    固定资产                      141,087,408.06                        143,637,954.46
    在建工程                          100,000.00                           100,000.00
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                          637,761.55                         24,375,487.87
    开发支出
    商誉
    长期待摊费用
    递延所得税资产                  2,380,922.25                          2,380,922.25
    其他非流动资产
    非流动资产合计                    288,391,016.45                        314,679,289.17
    资产总计                          915,208,556.04                        742,322,089.27流动负债:
                                        桂林莱茵生物科技股份有限公司 2013 年第一季度报告全文
    短期借款                            345,147,990.35                        343,457,104.68
    交易性金融负债
    应付票据
    应付账款                             13,532,345.34                         15,456,514.94
    预收款项                              1,274,645.22                           392,671.33
    应付职工薪酬                              6,751.40                          1,726,164.61
    应交税费                               -249,493.85                          1,614,855.47
    应付利息                                663,228.54                          1,291,005.17
    应付股利
    其他应付款                           51,498,263.24                         51,626,873.57
    一年内到期的非流动负债                6,536,440.00                         11,536,440.00
    其他流动负债
    流动负债合计                            418,410,170.24                        427,101,629.77非流动负债:
    长期借款                            120,000,000.00                        120,000,000.00
    应付债券
    长期应付款
    专项应付款                          179,909,426.92
    预计负债
    递延所得税负债
    其他非流动负债                       10,748,265.00                         10,748,265.00
    非流动负债合计                          310,657,691.92                        130,748,265.00
    负债合计                                729,067,862.16                        557,849,894.77所有者权益(或股东权益):
    实收资本(或股本)                  129,533,760.00                        129,533,760.00
    资本公积                             83,217,530.86                         83,217,530.86
    减:库存股
    专项储备
    盈余公积                              8,834,943.24                          8,834,943.24
    一般风险准备
    未分配利润                           -35,445,540.22                       -37,114,039.60
    外币报表折算差额
    所有者权益(或股东权益)合计            186,140,693.88                        184,472,194.50
    负债和所有者权益(或股东权益)总        915,208,556.04                        742,322,089.27
                                                             桂林莱茵生物科技股份有限公司 2013 年第一季度报告全文计
    法定代表人:姚新德                       主管会计工作负责人:周庆伟                      会计机构负责人:张为鹏3、合并利润表编制单位:桂林莱茵生物科技股份有限公司
                                                                                                          单位:元
                 项目                             本期金额                               上期金额
    一、营业总收入                                                95,142,400.97                         35,648,461.76
    其中:营业收入                                           95,142,400.97                         35,648,461.76
            利息收入
            已赚保费
            手续费及佣金收入
    二、营业总成本                                                93,284,910.29                         48,634,488.29
    其中:营业成本                                           75,091,629.37                         31,254,352.17
            利息支出
            手续费及佣金支出
            退保金
            赔付支出净额
            提取保险合同准备金净额
            保单红利支出
            分保费用
            营业税金及附加                                     1,817,798.35                            422,498.01
            销售费用                                           2,700,620.03                          2,576,267.79
            管理费用                                           5,629,164.91                          8,049,829.91
            财务费用                                           8,045,947.63                          6,331,540.41
            资产减值损失                                            -250.00
    加    :公允价值变动收益(损失以“-”号填列)
            投资收益(损失以“-”
                                                                 251,335.13                            161,994.00号填列)
            其中:对联营企业和合营企业的投资收益
            汇兑收益(损失以“-”号
                                                                -640,564.95                           -348,222.15填列)
    三、营业利润(亏损以“-”号填列)                             1,468,260.86                         -13,172,254.68
                                                               桂林莱茵生物科技股份有限公司 2013 年第一季度报告全文
       加   :营业外收入                                           533,626.39                            650,823.19
       减   :营业外支出                                           201,119.00                             16,842.88
             其中:非流动资产处置损失四、利润总额(亏损总额以“-”号
                                                                 1,800,768.25                         -12,538,274.37填列)
       减:所得税费用
    五、净利润(净亏损以“-”号填列)                               1,800,768.25                         -12,538,274.37
       其中:被合并方在合并前实现的净利润
       归属于母公司所有者的净利润                                1,805,506.51                         -12,527,545.75
       少数股东损益                                                 -4,738.26                             -10,728.62
    六、每股收益:                        --                                        --
       (一)基本每股收益                                                0.01                                   -0.1
       (二)稀释每股收益                                                0.01                                   -0.1
    七、其他综合收益                                                  -318,530.77                             66,329.55
    八、综合收益总额                                                 1,482,237.48                         -12,471,944.82
       归属于母公司所有者的综合收益
                                                                 1,486,975.74                         -12,461,216.20总额
       归属于少数股东的综合收益总额                                 -4,738.26                             -10,728.62
    法定代表人:姚新德                         主管会计工作负责人:周庆伟                      会计机构负责人:张为鹏4、母公司利润表编制单位:桂林莱茵生物科技股份有限公司
                                                                                                            单位:元
                  项目                              本期金额                               上期金额
    一、营业收入                                                    38,168,283.96                         33,316,589.87
       减:营业成本                                             25,808,543.35                         28,752,140.03
            营业税金及附加                                         141,227.82                            412,850.61
            销售费用                                             1,343,305.26                          1,747,237.27
            管理费用                                             4,267,331.14                          4,707,156.69
            财务费用                                             5,723,219.53                          5,659,722.58
            资产减值损失
       加:公允价值变动收益(损失以“-”号填列)
                                                             桂林莱茵生物科技股份有限公司 2013 年第一季度报告全文
         投资收益(损失以“-”号
                                                                 251,335.13                           161,994.00填列)
         其中:对联营企业和合营企业的投资收益
    二、营业利润(亏损以“-”号填列)                             1,135,991.99                         -7,800,523.31
    加:营业外收入                                              533,626.39                            92,396.58
    减:营业外支出                                                1,119.00                            16,642.88
         其中:非流动资产处置损失                                  1,119.00三、利润总额(亏损总额以“-”号
                                                               1,668,499.38                         -7,724,769.61填列)
    减:所得税费用
    四、净利润(净亏损以“-”号填列)                             1,668,499.38                         -7,724,769.61
    五、每股收益:                      --                                        --
    (一)基本每股收益                                                0.01                                 -0.06
    (二)稀释每股收益                                                0.01                                 -0.06六、其他综合收益
    七、综合收益总额                                               1,668,499.38                         -7,724,769.61
    法定代表人:姚新德                       主管会计工作负责人:周庆伟                      会计机构负责人:张为鹏5、合并现金流量表编制单位:桂林莱茵生物科技股份有限公司
                                                                                                         单位:元
                 项目                             本期金额                               上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                             66,672,028.23                         43,939,037.10
    客户存款和同业存放款项净增加额
    向中央银行借款净增加额
    向其他金融机构拆入资金净增加额
    收到原保险合同保费取得的现金
    收到再保险业务现金净额
    保户储金及投资款净增加额
    处置交易性金融资产净增加额
    收取利息、手续费及佣金的现金
                                         桂林莱茵生物科技股份有限公司 2013 年第一季度报告全文
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还                        1,633,703.12                          2,048,339.40
    收到其他与经营活动有关的现金        204,202,436.07                         50,740,871.02
    经营活动现金流入小计                     272,508,167.42                         96,728,247.52
    购买商品、接受劳务支付的现金        341,774,715.18                         32,148,290.70
    客户贷款及垫款净增加额
    存放中央银行和同业款项净增加额
    支付原保险合同赔付款项的现金
    支付利息、手续费及佣金的现金
    支付保单红利的现金
    支付给职工以及为职工支付的现
                                           8,150,561.47                          6,581,764.60金
    支付的各项税费                        1,403,648.49                          2,434,455.28
    支付其他与经营活动有关的现金         10,656,110.36                         12,874,579.84
    经营活动现金流出小计                     361,985,035.50                         54,039,090.42
    经营活动产生的现金流量净额                -89,476,868.08                        42,689,157.10二、投资活动产生的现金流量:
    收回投资收到的现金
    取得投资收益所收到的现金                251,335.13                           161,994.00
    处置固定资产、无形资产和其他长期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
    投资活动现金流入小计                         251,335.13                           161,994.00
    购建固定资产、无形资产和其他
                                           3,140,527.33                          3,696,534.50长期资产支付的现金
    投资支付的现金
    质押贷款净增加额
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
    投资活动现金流出小计                       3,140,527.33                          3,696,534.50
    投资活动产生的现金流量净额                 -2,889,192.20                        -3,534,540.50
                                                             桂林莱茵生物科技股份有限公司 2013 年第一季度报告全文三、筹资活动产生的现金流量:
       吸收投资收到的现金
       其中:子公司吸收少数股东投资收到的现金
       取得借款收到的现金                                    122,920,862.92                          40,000,000.00
       发行债券收到的现金
       收到其他与筹资活动有关的现金                          100,000,000.00                          25,500,000.00
    筹资活动现金流入小计                                         222,920,862.92                          65,500,000.00
       偿还债务支付的现金                                     11,287,100.00                          51,000,000.00
       分配股利、利润或偿付利息支付
                                                              12,123,791.59                           7,097,877.27的现金
       其中:子公司支付给少数股东的股利、利润
       支付其他与筹资活动有关的现金                          104,051,080.34                          51,041,759.58
    筹资活动现金流出小计                                         127,461,971.93                         109,139,636.85
    筹资活动产生的现金流量净额                                    95,458,890.99                         -43,639,636.85四、汇率变动对现金及现金等价物的
                                                                -372,753.42                             -82,308.05影响
    五、现金及现金等价物净增加额                                   2,720,077.29                          -4,567,328.30
       加:期初现金及现金等价物余额                           41,151,733.01                          74,764,663.71
    六、期末现金及现金等价物余额                                  43,871,810.30                          70,197,335.41
    法定代表人:姚新德                       主管会计工作负责人:周庆伟                      会计机构负责人:张为鹏6、母公司现金流量表编制单位:桂林莱茵生物科技股份有限公司
                                                                                                          单位:元
                 项目                             本期金额                               上期金额一、经营活动产生的现金流量:
       销售商品、提供劳务收到的现金                           61,632,008.44                          41,770,699.32
       收到的税费返还                                          1,633,703.12                           2,048,339.40
       收到其他与经营活动有关的现金                          204,130,423.94                            699,362.94
    经营活动现金流入小计                                         267,396,135.50                          44,518,401.66
       购买商品、接受劳务支付的现金                          295,661,621.83                          26,815,021.86
       支付给职工以及为职工支付的现
                                                               5,840,762.19                           3,511,575.44金
                                           桂林莱茵生物科技股份有限公司 2013 年第一季度报告全文
       支付的各项税费                        1,389,403.52                          1,149,836.59
       支付其他与经营活动有关的现金          6,352,248.36                          4,212,231.78
    经营活动现金流出小计                       309,244,035.90                         35,688,665.67
    经营活动产生的现金流量净额                  -41,847,900.40                         8,829,735.99二、投资活动产生的现金流量:
       收回投资收到的现金
       取得投资收益所收到的现金                251,335.13                           161,994.00
       处置固定资产、无形资产和其他长期资产收回的现金净额
       处置子公司及其他营业单位收到的现金净额
       收到其他与投资活动有关的现金
    投资活动现金流入小计                           251,335.13                           161,994.00
       购建固定资产、无形资产和其他
                                             1,224,450.00                              2,500.00长期资产支付的现金
       投资支付的现金
       取得子公司及其他营业单位支付的现金净额
       支付其他与投资活动有关的现金
    投资活动现金流出小计                         1,224,450.00                              2,500.00
    投资活动产生的现金流量净额                    -973,114.87                           159,494.00三、筹资活动产生的现金流量:
       吸收投资收到的现金
       取得借款收到的现金                    7,920,862.92
       发行债券收到的现金
       收到其他与筹资活动有关的现金        179,000,000.00                         44,000,000.00
    筹资活动现金流入小计                       186,920,862.92                         44,000,000.00
       偿还债务支付的现金                   11,287,100.00                         41,000,000.00
       分配股利、利润或偿付利息支付
                                             8,309,624.93                          5,995,124.50的现金
       支付其他与筹资活动有关的现金        106,000,000.00                         38,541,759.58
    筹资活动现金流出小计                       125,596,724.93                         85,536,884.08
    筹资活动产生的现金流量净额                  61,324,137.99                        -41,536,884.08四、汇率变动对现金及现金等价物的
                                              -371,606.44                            -82,158.88影响
    五、现金及现金等价物净增加额                18,131,516.28                        -32,629,812.97
                                                      桂林莱茵生物科技股份有限公司 2013 年第一季度报告全文
    加:期初现金及现金等价物余额                       10,785,342.58                         60,736,523.55
    六、期末现金及现金等价物余额                           28,916,858.86                         28,106,710.58
    法定代表人:姚新德                 主管会计工作负责人:周庆伟                     会计机构负责人:张为鹏二、审计报告第一季度报告是否经过审计□ 是 √ 否
                                                                        桂林莱茵生物科技股份有限公司
                                                                                法定代表人:姚新德
                                                                               二〇一三年四月二十四日
数据加载中...
prevnext
手机查看股票